According to early findings of a pilot study presented at a conference in the US this week, the controversy surrounding prostate cancer screening could be about to change: a UK company has developed a panel of biomarkers that appears to distinguish samples of prostate cancer from samples of benign prostate disease and healthy prostate tissue 90 per cent of the time, considerably higher than current diagnostic tests.
Oxford Gene Technology (OGT) said in their pilot study involving 73 prostate cancer and 60 control samples, they identified a set of biomarkers that differentiated prostate cancer from control samples with both "sensitivity and specificity above 90 per cent."
Read more at Medical News Today.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment